Polyrizon completes contracts for five U.S. sites in NASARIX first-in-human seasonal allergic rhinitis trial

PUBT · 3d ago
Polyrizon completes contracts for five U.S. sites in NASARIX first-in-human seasonal allergic rhinitis trial
  • Polyrizon completed contracts for all five U.S. sites for a first-in-human trial of NASARIX Allergy Blocker in seasonal allergic rhinitis.
  • No clinical results have been presented; efficacy and safety data are expected in the future once enrollment and follow-up are completed.
  • The study aims to show symptom relief versus saline control, with acceptable tolerability, under real-world seasonal allergen exposure.
  • Up to 120 patients are planned, with recruitment timed to allergy seasons, moving the program from setup into execution.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020732PRIMZONEFULLFEED9820207) on September 02, 2026, and is solely responsible for the information contained therein.